While the current influenza A H1N1 2009 virus is known to be sensitive to neuraminidase-inhibitor chemoprophylaxis, it has limited diversity at neutralizing antibody binding sites and overall mortality rates comparable with seasonal influenza (1) ; variations at numerous sites within the influenza A genome are predicted to alter these characteristics, with potentially important consequences for healthcare provision.